Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 5.736 billion yuan in 2024, a year-on-year increase of 3.9%, but the net profit attributable to shareholders decreased by 33.5% to 503 million yuan. In Q1 2025, revenue was 949 million yuan, down 13.5%, with a net profit of 28 million yuan, down 84.0%. Due to rising costs and increased competition, profit forecasts for 2025-2026 have been revised downwards, with new estimates for net profit at 672 million yuan for 2025, 803 million yuan for 2026, and 927 million yuan for 2027. The expected EPS for these years is 1.59, 1.90, and 2.19 yuan respectively, with corresponding PE ratios of 25.4, 21.2, and 18.4 times [5][8][11]. Financial Performance - In 2024, the company achieved revenue of 5.736 billion yuan, with a year-on-year growth of 3.9%. The net profit attributable to shareholders was 503 million yuan, reflecting a decline of 33.5%. For Q1 2025, revenue was 949 million yuan, down 13.5%, and net profit was 28 million yuan, down 84.0% [5][8]. - The gross margin for 2024 was 73.7%, a slight decrease of 0.2 percentage points, while Q1 2025 saw an improvement in gross margin to 77.5%, an increase of 5.4 percentage points [6][12]. - The company’s operating expenses increased in 2024, with sales, management, and R&D expense ratios rising by 2.7, 1.5, and -0.3 percentage points respectively. In Q1 2025, these ratios further increased by 9.3, 5.5, and 3.1 percentage points, indicating higher costs due to intensified market competition [6][12]. Brand and Channel Performance - The main brand, Winona, focuses on sensitive skin solutions, enhancing customer value through a "single product + set" strategy. The second-tier brands, including Winona Baby and Aikeman, have shown strong performance in their respective markets. The company is also optimizing its online channels and has begun to enter mainstream beauty channels in Thailand [7][8]. - In 2024, the revenue from the skincare segment was 4.801 billion yuan, down 1.4%, while the makeup segment saw significant growth, achieving 551 million yuan, an increase of 226.5% [6][8]. Valuation Metrics - The company’s total market capitalization is 170.67 billion yuan, with a current stock price of 40.29 yuan. The stock has a one-year high of 74.00 yuan and a low of 37.46 yuan [1][8]. - The projected P/E ratios for 2025, 2026, and 2027 are 25.4, 21.2, and 18.4 respectively, indicating a reasonable valuation based on expected earnings growth [5][8]. Summary of Financial Forecasts - The company is expected to achieve revenues of 6.277 billion yuan in 2025, 7.023 billion yuan in 2026, and 7.962 billion yuan in 2027, with corresponding net profits of 672 million yuan, 803 million yuan, and 927 million yuan [8][11]. - The gross margin is projected to stabilize around 73.8% from 2025 to 2027, while the net profit margin is expected to improve gradually from 10.5% in 2025 to 11.5% in 2027 [8][12].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a 28.6% increase in non-net profit attributable to the parent company for Q1 2025, indicating sustained upward momentum [4] - The company's revenue for 2024 reached 2.97 billion yuan, a year-on-year increase of 33.4%, with a net profit of 342 million yuan, up 31.7% [4] - For Q1 2025, the company achieved revenue of 847 million yuan, a 28.0% increase, and a net profit of 135 million yuan, up 22.1% [4] - The projected net profits for 2025-2027 are 456 million, 597 million, and 763 million yuan respectively, with corresponding EPS of 1.14, 1.49, and 1.90 yuan [4] Financial Performance Summary - The company’s revenue and net profit growth rates for 2024 are 33.4% and 31.7% respectively, with a gross margin of 73.7% [7] - The revenue breakdown for 2024 shows significant growth in various product categories: eye care (+60.8%), skincare (+21.6%), cleansing (+8.8%), and beauty products (+40.5%) [5] - The company’s gross margin for Q1 2025 is reported at 76.1%, reflecting a 1.4 percentage point increase [5] - The company’s operating expenses have been managed effectively, with sales expenses increasing due to enhanced brand investment [5] Product and Brand Performance - The company has seen strong performance in its key products, with the "Little Red Pen" achieving a GMV of 530 million yuan, a 146% increase, and the "Little Gold Needle" reaching 350 million yuan, up 96% [5] - The brand "Mame" and "Lianhuo" both reported revenue growth exceeding 30% and 40% respectively [5] - The company’s user engagement metrics show a 31% increase in active brand members and a 48% increase in repurchase amounts [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report indicates that the refrigerant market is experiencing a sustained upward trend, with a gradual emergence of a main bullish market [5] - The company achieved a revenue of 5.8 billion yuan in Q1 2025, representing a year-on-year increase of 6.05%, and a net profit attributable to shareholders of 809 million yuan, up 160.64% year-on-year [5] - The report maintains profit forecasts for 2025-2027, expecting net profits of 5.128 billion, 7.285 billion, and 8.535 billion yuan respectively, with corresponding EPS of 1.90, 2.70, and 3.16 yuan [5] Financial Performance Summary - In Q1 2025, the company's revenue from various segments was as follows: fluorochemical raw materials (326 million yuan, +26.90%), refrigerants (2.618 billion yuan, +64.63%), and other segments [6] - The average price of refrigerants in Q1 2025 increased significantly, with a year-on-year rise of 58.08% to 37,504 yuan/ton [6] - The company’s total revenue for 2023 was 20.655 billion yuan, with a projected increase to 28.642 billion yuan in 2025, reflecting a year-on-year growth of 17.1% [8] Market Trends - The report highlights a continuous increase in air conditioning production in China, with expected growth rates of 9.9%, 14.1%, and 14.3% from May to July 2025 [7] - The demand for air conditioning in overseas markets is also strong, with significant sales increases reported by major manufacturers [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company experienced significant new customer growth in Q1 2025, with revenue reaching 5.35 billion yuan, a year-on-year increase of 12.3%. However, the net profit attributable to the parent company was 760 million yuan, reflecting a decrease of 3.2% due to the impact of new factory ramp-up on profitability [7][8] - The report anticipates improved gross margins in Q2 2025 as scale effects and new factory ramp-up take effect, with long-term optimism regarding new customer volume and increased market share from existing customers [7][8] Financial Summary - Q1 2025 revenue was 5.35 billion yuan, with a volume increase of 8.24% and a price increase of 3.8%. The gross margin was 22.9%, down 5.5 percentage points due to initial training periods for new employees at new factories [7][8] - The company plans to accelerate the construction of new factories to meet the growing demand from new customers, with two new factories in Indonesia and Sichuan launched in Q1 2025, and further expansions planned in Vietnam and Indonesia [7] - The net profit forecast for 2025-2027 has been adjusted to 4.1 billion, 4.76 billion, and 5.51 billion yuan respectively, with corresponding P/E ratios of 16.1, 13.8, and 12.0 times [7][9] Operational Capability - As of Q1 2025, the company had a net operating cash flow of 1.21 billion yuan, with inventory at 3.67 billion yuan and accounts receivable at 3.31 billion yuan, indicating a stable operational capability [8]

股票投资评级 买入 |维持 个股表现 2024-04 2024-07 2024-09 2024-11 2025-02 2025-04 -26% -22% -18% -14% -10% -6% -2% 2% 6% 10% 14% 18% 福瑞达 美容护理 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 7.55 | | --- | --- | | 总股本/流通股本（亿股）10.17 | / 10.17 | | 总市值/流通市值（亿元）77 | / 77 | | 52 周内最高/最低价 | 8.91 / 5.89 | | 资产负债率(%) | 20.2% | | 市盈率 | 31.46 | | 第一大股东 | 山东省商业集团有限公 | | 司 | | 研究所 证券研究报告：美容护理 | 公司点评报告 发布时间：2025-04-29 分析师:李媛媛 SAC 登记编号:S1340523020001 Email:liyuanyuan@cnpsec.com 福瑞达(600223) 颐莲保持高增，静待瑷尔博士拐点 l 事件回顾 公司公布 25Q1 季报，25Q1 实现收入 8.8 亿元，同比-1.6 ...

证券研究报告·公司研究简报·软件开发 德赛西威（002920） 外延内生并驱，走向 AI 时代 2025 年 04 月 29 日 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 21,908 | 27,618 | 36,938 | 46,173 | 56,469 | | 同比（%） | 46.71 | 26.06 | 33.75 | 25.00 | 22.30 | | 归母净利润（百万元） | 1,547 | 2,005 | 2,756 | 3,670 | 4,710 | | 同比（%） | 30.57 | 29.62 | 37.45 | 33.19 | 28.32 | | EPS-最新摊薄（元/股） | 2.79 | 3.61 | 4.97 | 6.61 | 8.49 | | P/E（现价&最新摊薄） | 37.83 | 29.19 | 21.24 | 15.94 | 12.42 | [Table_Tag] [ ...

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 97.16, compared to the current price of RMB 74.47 [1][10]. Core Insights - The company is experiencing rapid growth in emerging businesses, leading to improved profitability. The focus on polypeptide capabilities and global expansion is expected to drive long-term growth [1][10]. - In Q1 2025, the company reported revenue of RMB 1.54 billion, a 10.10% increase year-on-year, and a net profit attributable to shareholders of RMB 327 million, up 15.83% [10]. - The gross profit margin for Q1 2025 was 42.54%, showing a year-on-year decline of 0.98 percentage points but an increase of 3.28 percentage points quarter-on-quarter [10]. Financial Summary - Revenue projections for 2025-2027 are RMB 6.63 billion, RMB 7.79 billion, and RMB 9.32 billion, respectively, with expected growth rates of 14.2%, 17.5%, and 19.5% [3][5]. - Net profit attributable to shareholders is forecasted to be RMB 1.09 billion in 2025, RMB 1.28 billion in 2026, and RMB 1.53 billion in 2027, reflecting growth rates of 15.1%, 16.8%, and 19.5% [3][5]. - The earnings per share (EPS) for 2025-2027 are projected at RMB 3.03, RMB 3.54, and RMB 4.23, respectively [3][10]. Business Performance - The small molecule CDMO business remained stable, while emerging business revenues grew over 80% year-on-year, with a gross profit margin of 33.05%, up 15.75 percentage points from 2024 [10]. - The company secured a total order backlog of USD 1.052 billion, representing a growth of over 20% year-on-year, ensuring stable revenue growth [10]. - The European R&D and pilot base commenced operations in August 2024, contributing to the expansion of the company's capabilities [10].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for its stock performance relative to the benchmark index [4][12]. Core Insights - The company has returned to profitability in Q1 2025, with a significant increase in revenue and net profit compared to the previous year. The revenue for Q1 2025 was 2.02 billion yuan, up 52.22% year-on-year, and the net profit reached 302 million yuan, a staggering increase of 1115.29% [2][4]. - The company is focusing on key product launches, including the new game "Zhu Xian World," which is expected to strengthen its position in the classic game category. The company is also optimizing its gaming business by discontinuing underperforming projects and concentrating resources on successful titles [3][4]. Financial Performance Summary - In 2024, the company reported a revenue of 5.57 billion yuan, a decrease of 28.50% year-on-year, and a net loss of 1.29 billion yuan. However, the first quarter of 2025 showed a strong recovery with a revenue of 2.02 billion yuan and a net profit of 302 million yuan [2][6]. - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.35 yuan, 0.64 yuan, and 0.77 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 38, 20, and 17 [4][6]. Business Strategy and Development - The company is implementing a "quality over quantity" strategy in its film and television business, reducing investment risks and focusing on short-form content. This includes the launch of a micro-drama channel "Her World" to diversify its creative capabilities [3]. - The company is also enhancing its esports ecosystem by organizing events such as "CAC 2025," which aims to solidify its presence in the competitive gaming market [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [6][8]. Core Insights - The company has shown robust revenue growth in 2024, achieving an operating income of 546.87 million yuan, a year-on-year increase of 14.50%. However, the net profit attributable to the parent company decreased by 37.68% to 80.27 million yuan [3][6]. - In the first quarter of 2025, the company returned to a rapid growth trajectory with a revenue of 66.48 million yuan, marking a year-on-year increase of 51.43% [3][4]. - The software business is experiencing significant growth, particularly in AI-enabled semiconductor design and manufacturing, with the software development and licensing segment achieving a revenue of 159 million yuan, up 70.33% year-on-year [3][4]. Financial Performance - The company reported a net profit of -13.71 million yuan in Q1 2025, indicating a significant narrowing of losses compared to previous periods [3]. - The company has maintained a high level of R&D investment, with R&D expenses amounting to 276.56 million yuan, representing 50.57% of operating income, a 33.49% increase year-on-year [5]. - Revenue forecasts for 2025-2027 are projected at 688.69 million yuan, 852.77 million yuan, and 1.045 billion yuan respectively, with net profits expected to reach 107 million yuan, 140.11 million yuan, and 179.21 million yuan [6][9]. Product Development - The company has launched several AI-driven platforms and tools, including the INF-AI semiconductor AI application platform and the SemiMind large model platform, which enhance design and manufacturing efficiency [4][5]. - The company is one of the few EDA firms that provide comprehensive yield management services through a combination of software and hardware solutions, addressing the increasing defect rates in semiconductor manufacturing [5]. Market Position - The company is positioned as a leading supplier of EDA software and wafer-level electrical testing equipment, with significant growth potential aligned with the global integrated circuit industry [6]. - The report highlights the company's ability to adapt to evolving semiconductor processes and the introduction of new EDA software to meet advanced manufacturing needs [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company experienced significant new customer growth in Q1 2025, with revenue reaching 5.35 billion yuan, a year-on-year increase of 12.3%. However, the net profit attributable to the parent company decreased by 3.2% to 760 million yuan due to the initial efficiency challenges of new factories [7][8] - The report anticipates improved gross margins in Q2 2025 as scale effects and new factory ramp-up contribute positively. Long-term prospects remain optimistic due to the expansion of new customer orders and increased market share from existing clients [7][8] Financial Summary - Q1 2025 revenue: 5.35 billion yuan (YoY +12.3%) - Q1 2025 net profit: 760 million yuan (YoY -3.2%) - Q1 2025 gross margin: 22.9% (down 5.5 percentage points) - Q1 2025 net profit margin: 14.2% (down 2.3 percentage points) [7][8] - Expected net profit for 2025-2027: 4.1 billion, 4.76 billion, and 5.51 billion yuan respectively [7] Operational Insights - Q1 2025 sales volume: 49 million pairs (YoY +8.24%), with an average price of 109 yuan per pair (YoY +3.8%) [7] - The company is accelerating the construction of new factories to meet the rising demand from new clients such as Adidas and New Balance, with plans to open two new factories in Indonesia and Sichuan in Q1 2025 [7] - As of Q1 2025, the company employed 184,000 people, a 17% increase YoY, with expectations of a slowdown in hiring in Q2 2025 [8] Financial Projections - Revenue projections for 2025-2027: 27.66 billion, 31.68 billion, and 36.18 billion yuan respectively [9] - Expected net profit margins for 2025-2027: 14.8%, 15.0%, and 15.2% respectively [9] - P/E ratios for 2025-2027: 16.1, 13.8, and 12.0 respectively [9]